These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 25670372

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
    Begley DJ.
    Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The blood-brain barrier: bottleneck in brain drug development.
    Pardridge WM.
    NeuroRx; 2005 Jan; 2(1):3-14. PubMed ID: 15717053
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Hurdles with using in vitro models to predict human blood-brain barrier drug permeability: a special focus on transporters and metabolizing enzymes.
    Shawahna R, Decleves X, Scherrmann JM.
    Curr Drug Metab; 2013 Jan; 14(1):120-36. PubMed ID: 23215812
    [Abstract] [Full Text] [Related]

  • 10. The concept of fraction of drug transported (ft ) with special emphasis on BBB efflux of CNS and antiretroviral drugs.
    Prasad B, Unadkat JD.
    Clin Pharmacol Ther; 2015 Apr; 97(4):320-3. PubMed ID: 25669655
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. From naturally-occurring neurotoxic agents to CNS shuttles for drug delivery.
    Soddu E, Rassu G, Giunchedi P, Sarmento B, Gavini E.
    Eur J Pharm Sci; 2015 Jul 10; 74():63-76. PubMed ID: 25892455
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 1. Anti-infective drugs.
    Adenot M, Perriere N, Scherrmann JM, Lahana R.
    Chemotherapy; 2007 Jul 10; 53(1):70-2. PubMed ID: 17202814
    [Abstract] [Full Text] [Related]

  • 15. Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review.
    Bicker J, Alves G, Fortuna A, Falcão A.
    Eur J Pharm Biopharm; 2014 Aug 10; 87(3):409-32. PubMed ID: 24686194
    [Abstract] [Full Text] [Related]

  • 16. Prodrug approaches to reduce hyperexcitation in the CNS.
    Vytla D, Combs-Bachmann RE, Hussey AM, McCarron ST, McCarthy DS, Chambers JJ.
    Adv Drug Deliv Rev; 2012 May 15; 64(7):666-85. PubMed ID: 22138074
    [Abstract] [Full Text] [Related]

  • 17. Nanobiotechnology-based strategies for crossing the blood-brain barrier.
    Jain KK.
    Nanomedicine (Lond); 2012 Aug 15; 7(8):1225-33. PubMed ID: 22931448
    [Abstract] [Full Text] [Related]

  • 18. [The blood-brain barrier and drug delivery in the central nervous system].
    Loch-Neckel G, Koepp J.
    Rev Neurol; 2010 Aug 15; 51(3):165-74. PubMed ID: 20645267
    [Abstract] [Full Text] [Related]

  • 19. Current State and Future Perspectives in QSAR Models to Predict Blood- Brain Barrier Penetration in Central Nervous System Drug R&D.
    Morales JF, Montoto SS, Fagiolino P, Ruiz ME.
    Mini Rev Med Chem; 2017 Aug 15; 17(3):247-257. PubMed ID: 27739359
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.